Dissociation of bone formation markers in bone metastasis of prostate cancer

British Journal of Cancer

Volumn 75, Issue 11, 1997, Pages 1601-1604

  Koizumi, M ^a   Maeda, H ^a   Yoshimura, K ^a   Yamauchi, T ^a   Kawai, T ^a   Ogata, E ^a  

^a CANCER INSTITUTE HOSPITAL   (Japan)

Author keywords

Bone gla protein; Bone metastasis; Bone specific alkaline phosphatase; Carboxy terminal propeptide of type I procollagen; Prostate cancer

Indexed keywords

ALKALINE PHOSPHATASE; OSTEOCALCIN; PROCOLLAGEN; TUMOR MARKER;

ADULT; AGED; ARTICLE; BONE METASTASIS; BONE SCINTISCANNING; CANCER GROWTH; HUMAN; MAJOR CLINICAL STUDY; MALE; OSSIFICATION; PRIORITY JOURNAL; PROSTATE CANCER;

EID: 0030978403     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1997.273     Document Type: Article

References (17)

1. Aoki J, Yamamoto I, Hino M, Shigeno C, Kitamura N, Itoh H, Torizuka K, Itoh T and Furuta M (1986) Sclerotic bone metastasis: radiologie-pathologic correlation. Radiology 159: 127-132
2. Arai Y, Takeuchi H, Oishi K and Yoshida O (1992) Osteocalcin: is it a useful marker of bone metastasis and response to treatment in advanced prostate cancer? Prostate 20: 169-177
3. Calvo MS, Eyre DR and Gundberg CM (1996) Molecular basis and clinical application of biological markers of bone turnover. Endocrine Rev 17: 333-368
4. Ducy P, Desbois C, Boyce B, Pinero G, Story B, Dunstan C, Smith E, Bonadio J, Goldstein S, Gundberg C, Bradley A and Karsenty G (1996) Increased bone formation in osteocalcin-deficient mice. Nature 382: 448-452
5. Francini G, Bigazzi S, Leone V and Gennaric C (1988) Serum osteocalcin concentration in patients with prostatic cancer. Am J Clin Oncol 11 (suppl. 2): S3-S87
6. Francini G, Petrioli R, Manganelli A, Cintorino M, Marsili S, Aquino A and Mondillo S (1993) Weekly chemotherapy in advanced prostatic cancer. Br J Cancer 67: 1430-1436
7. Koizumi M, Yamada Y, Takiguchi T, Nomura E, Furukawa M, Kitahara T, Maeda H, Takahashi S, Aiha K and Ogata E (1995) Bone metabolic markers in bone metastasis. J Cancer Res Clin Oncol 121: 542-548
8. Kylmala T, Tammela TLJ, Risteli L, Risteli J, Kontturi M and Elomaa I (1995) Type-I collagen degradation product (ICTP) gives information about the nature of bone metastasis and has prognostic value in prostate cancer. Br J Cancer 71: 1061-1064
9. Maeda H, Koizumi M, Yoshimura K, Yamauchi T, Kawai C and Ogata E (1997) Correlation of bone metabolic markers and hone scan in prostate cancer. J Urol 157: 539-543
10. Pollen JJ, Witztun KF, Ashburn WL (1984) The flare phenomenon on radionuclide bone scan in metaslatic prostate cancer. AJR 142: 773-776
11. Price PA, Williamson MK, Haba T, Dell RB and Lee WS (1982) Excessive mineralization with growth plate closure in rats on chronic warfarin treatment. Proc Natl Acad Sci USA 79: 7734-7738
12. Risteli I, and Risteli J (1993) Biochemical markers of hone metabolism. Ann Med 25: 385-393
13. Sano M, Kushida K, Takahashi M, Ohishi T, Kawana K, Okada M and Inoue T (1994) Urinary pyridinoline and deoxypyridinoline in prostate cancer patients with bone metastasis. Br J Cancer 70: 701-703
14. Shin WJ, Wiertzbinski B, Collins J, Magoun S, Chen IW and Ryo UY (1990) Serum osteocalcin measurements in prostate carcinoma patients with skeletal deposits shown by bone scintigram: comparison with serum PSA/PAP measurements. J Nucl Med 31: 1486-1489
15. Slack MH and Murrhy GP (1984) Criteria for evaluating patient response to treatment modalities for prostatic cancer, Urol Clin N Am 11: 337-342
16. Stein GS, Lian JB and Owen TA (1990) Relationship of cell growth to the regulation of tissue-specific gene expression. during osteoblast differentiation. FASEB J 4: 3111-3123
17. Zhou H, Choong P, McCarthy R, Chou ST, Martin TJ and Ng KW (1994) In situ hybridization to show sequential expression of osteoblast gene markers during bone formation in vivo. J Bone Miner Res 9: 1489-1499